IPP Bureau
Zydus Pharmaceuticals USA receives tentative approval for schizophrenia drug
By IPP Bureau - December 11, 2021
The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
SPARC to present clinical data on vodobatinib
By IPP Bureau - December 11, 2021
Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML
Venus Remedies gets approval under the PLI scheme
By IPP Bureau - December 11, 2021
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
Cipla aims to improve access to nebulisers in PHCs
By IPP Bureau - December 11, 2021
The company will donate 5000 nebulizers to primary health care centres in rural India
Alembic acquires stake in RIGlmmune
By IPP Bureau - December 11, 2021
The company is focused on the development of novel treatments for RNA viruses
Indian government approves eight firms for PLI scheme
By IPP Bureau - December 10, 2021
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
Govt includes seven more companies under PLI scheme
By IPP Bureau - December 10, 2021
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
.jpg "Medicago and GSK’s plant based Covid-19 vaccine candidate show promise in Phase 3 trials")
Medicago and GSK’s plant based Covid-19 vaccine candidate show promise in Phase 3 trials
By IPP Bureau - December 10, 2021
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Dr Reddy’s launch Venlafaxine ER tablets in the US
By IPP Bureau - December 10, 2021
The tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.
China approves Brii Bio’s antibody combination to neutralise Covid-19
By IPP Bureau - December 10, 2021
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Zydus receives USFDA approval for Phase2(b)/3 trial of Saroglitazar
By IPP Bureau - December 10, 2021
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
Aerogen partners with CanSinoBIO for aerosolised Covid-19 vaccine
By IPP Bureau - December 10, 2021
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
Algorithmic Biologics receives CE mark for Tapestry platform
By IPP Bureau - December 10, 2021
The platform’s technology works as a compression algorithm for molecular testing
Lupin enters the diagnostics business
By IPP Bureau - December 10, 2021
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
Gland Pharma receives tentative approval for Cangrelor
By IPP Bureau - December 09, 2021
Gland Pharma believes that they are amongst one of the first to file for this product and may be eligible for 180 days of generic drug exclusivity
